Waylis Therap Company Profile

✉ Email this page to a colleague

WAYLIS THERAP has eleven approved drugs.

There is one US patent protecting WAYLIS THERAP drugs.

There are twenty-four patent family members on WAYLIS THERAP drugs in fourteen countries and five supplementary protection certificates in four countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Waylis Therap	COREG CR	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	022012-002	Oct 20, 2006	AB	RX	Yes	No	8,101,209*PED	⤷ Sign Up			Y	⤷ Sign Up
Waylis Therap	COREG	carvedilol	TABLET;ORAL	020297-003	Sep 14, 1995	AB	RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Waylis Therap	MYLERAN	busulfan	TABLET;ORAL	009386-001	Approved Prior to Jan 1, 1982		RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Waylis Therap	JALYN	dutasteride; tamsulosin hydrochloride	CAPSULE;ORAL	022460-001	Jun 14, 2010	AB	RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Waylis Therap	LUNESTA	eszopiclone	TABLET;ORAL	021476-002	Dec 15, 2004	6,444,673*PED	⤷ Sign Up
Waylis Therap	COREG	carvedilol	TABLET;ORAL	020297-001	Sep 14, 1995	5,902,821*PED	⤷ Sign Up
Waylis Therap	COREG CR	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	022012-002	Oct 20, 2006	RE40000*PED	⤷ Sign Up
Waylis Therap	COREG	carvedilol	TABLET;ORAL	020297-004	May 29, 1997	5,760,069*PED	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Capsules	40 mg	➤ Subscribe	2007-12-21
➤ Subscribe	Capsules	0.5 mg	➤ Subscribe	2007-10-29
➤ Subscribe	Tablets	1 mg, 2 mg and 3 mg	➤ Subscribe	2008-12-15
➤ Subscribe	Extended-release Capsules	10 mg and 20 mg	➤ Subscribe	2008-03-18
➤ Subscribe	Extended-release Capsules	80 mg	➤ Subscribe	2007-11-19
➤ Subscribe	Capsule	0.5 mg/0.4 mg	➤ Subscribe	2010-10-26

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0268956	1999C0030	Belgium	⤷ Sign Up	PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
0719278	03C0030	France	⤷ Sign Up	PRODUCT NAME: DUTASTERIDE; NAT. REGISTRATION NO/DATE: NL 28 131 20030327; FIRST REGISTRATION: SE - 17 871 20020719
0268956	SPC/GB98/040	United Kingdom	⤷ Sign Up	PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
0719278	23/2003	Austria	⤷ Sign Up	PRODUCT NAME: DUTASTERIDE, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SOLVATES; NAT. REGISTRATION NO/DATE: 1-24844, 1-24845 20030217; FIRST REGISTRATION: SE 17871, 17872 20020719
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.